LIMS technologies (laboratory information management systems) are changing to meet the newest demands of scientific research. A recent article written by Kevin Davies of BioIT World illustrates how a LIMS can help manage the complex sampling required for next-gen sequencing (NGS) used in cancer diagnostics. Laying the Foundation for Next-Gen Cancer Diagnostics illustrates the innovative work being done by Cambridge-based Foundation Medicine, one of the leaders in this relatively new field. For an in-depth look at the work of Foundation Medicine and the LIMS solution that is helping its scientists keep track of all of that genetic data, another good article published by 20/20 Pharma includes an interview with Mike Pellini, Foundation Medicine’s CEO and Dave Champagne, VP and General Manager for the Informatics business at Thermo Fisher Scientific – This Time It’s Personal – How Next-Gen Sequencing and Convergent Informatics are Enabling Personalized Cancer Medicine.
Dr. Bruce Friedman, M.D. Professor Emeritus at the University of Michigan School of Medicine, Department of Pathology has said, “One of the major goals of the translational research movement has been to bridge the gap from bench to bedside and any initiative to blend the LIS with the LIMS can be understood as an extension of this quest. The lesson from all of this is obvious. We now need to make an effort to understand the relative strengths of LIS and LIMS and proceed to develop new systems that capture the best features of each of them.”
The Clinical LIMS was developed to bridge the gap from bench to bedside and provide this convergence of functionality needed by researchers and clinicians.
Like what you are learning?
To read more about the Clinical LIMS solution developed for clinical and molecular diagnostics, a good source of information is CLINICAL LIMS Resources, which includes more articles and technical information.
Let us know if this article and case study was helpful to you in the Comments box below. We look forward to your comments!